Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook

Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.

Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
• Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
• Flowers Foods, Inc. (FLO) Reports In-Line Q1 EPS; Adjusts FY12 EPS Growth Outlook

Create E-mail Alert Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter